Valeant Will Become Bausch Health Companies Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald
May 8, 2018 2:15 PM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $25 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q1 beat and raise.
"We think a greater appreciation for Valeant's solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+,"... More
